Medicare drug price negotiation now has a permanent rulebook. The Centers for Medicare & Medicaid Services (CMS) issued a final rule on Nov. 5, 2026, that writes the program’s procedures into regulation for 2029 and later, according to the agency’s press release. The rule takes effect Dec. 5, 2026. Nothing in it changes a copay this winter. It does set the process that will decide which drugs are negotiated next, starting with up to 20 selections due by Feb. 1, 2027. This explainer covers what the rule does, what it leaves open, and what Medicare enrollees can and cannot take from it.
What the Medicare drug price negotiation rule does
CMS’s fact sheet for rule CMS-4215-F says the regulation codifies Medicare drug price negotiation policy for initial price applicability year 2029 and later. The program’s earlier years, 2026 through 2028, were carried out through agency guidance. The new rule also adds policies and revises some earlier ones based on what CMS learned while running the program. The American Hospital Association, in its summary of the rule, says it mostly formalizes existing guidance while adding some new provisions and changes.
The table below lists the main dates in the CMS documents on Medicare drug price negotiation.
| Date | What happens | Source |
|---|---|---|
| Nov. 5, 2026 | CMS issues the final rule | CMS press release |
| Dec. 5, 2026 | The rule takes effect | CMS fact sheet |
| Feb. 1, 2027 | CMS selects up to 20 drugs for the fourth negotiation cycle | CMS press release |
| Feb. 28 after selection | Manufacturers must sign the program agreement | CMS fact sheet |
| 2029 | First prices under the new rule apply | CMS press release |
CMS plans separate guidance in fall 2026 on how the 2028 negotiated prices will be put into effect, including for Part B drugs. The fact sheet says the agency intends to write the effectuation policies for 2029 and later into rulemaking during calendar year 2027.
How CMS picks drugs for Medicare drug price negotiation
For each price applicability year starting with 2029, CMS selects up to 20 drugs covered under Part D, payable under Part B, or both. It can also select drugs for renegotiation. The fact sheet describes a sequence in which CMS sends an initial offer with a short justification, the manufacturer replies with a counteroffer, and the two sides can hold meetings and exchange further prices. CMS then publishes the agreed price, called the maximum fair price, along with an explanation. The stated goal is the lowest maximum fair price for each selected drug.
In Medicare drug price negotiation, a drug stops being eligible if the FDA approves a generic or licenses a biosimilar that references it and the product is subject to what the rule calls bona fide marketing. The rule sets out how CMS reviews those determinations and monitors continued marketing.
What is new in the final Medicare drug price negotiation rule
The CMS press release names several provisions. Each is listed below with the agency’s description.
- Fixed combination drugs. If two products share a manufacturer and an active ingredient, and one adds an ingredient that creates a new formulation and route of administration, CMS will treat them as one potential qualifying drug. The fact sheet gives the example of a product containing an active ingredient plus hyaluronidase, grouped with the same company’s version containing only the active ingredient. CMS says the policy is meant to stop manufacturers from moving patients to a new formulation to avoid the negotiated price.
- Small biotech price floor. As required by law, CMS may not offer or accept a counteroffer below a set floor for certain eligible small biotech drugs. The floor applies to price years 2029 and 2030.
- Part D formulary and payment rules. Part D plans must include selected drugs that have a negotiated price in effect, and they must limit what they pay dispensing entities to the negotiated price plus any dispensing fees.
- Renegotiation. CMS codifies the criteria and data it will use to pick drugs for renegotiation, and it will consider the earlier agreed price as part of that review.
CMS Administrator Dr. Mehmet Oz said the rule “provides additional tools” for negotiating better deals, according to the press release.
What the Medicare drug price negotiation rule means for enrollees
The CMS press release does not directly describe changes to what enrollees pay out of pocket. It says the rule is meant to help CMS achieve greater savings for taxpayers and beneficiaries and to improve health outcomes. It does not give a dollar savings estimate, and it does not give a count of drugs beyond the “up to 20” for the fourth cycle. Those omissions matter for anyone reading headlines that describe the rule as a price cut. The first Medicare drug price negotiation prices under this rule apply in 2029, so the rule cannot change a 2027 plan’s costs.
For a Medicare enrollee deciding on a 2027 plan, the practical guidance is unchanged. The Jolt Journal’s guide to the Part D changes to check before Dec. 7 covers the plan-year decisions that do apply now, and its report on Medicare scams during open enrollment lists red flags for callers and ads that cite policy news to sell plans.
The two dates also sit close together on the calendar. Open enrollment ends Dec. 7, and the rule takes effect Dec. 5. The rule governs the program for 2029 onward, so it is not a reason to change a 2027 plan choice.
What the Medicare drug price negotiation coverage does not settle
The documents on Medicare drug price negotiation leave several questions unanswered:
- Which drugs CMS will pick for the fourth cycle. The selections are due by Feb. 1, 2027.
- How much the program will save. The press release gives no estimate.
- How the fall 2026 guidance will handle Part B drugs in 2028.
- How manufacturers will respond. The fact sheet describes a signing deadline and a voluntary evidence process, but it does not forecast participation.
The AHA summary adds no stakeholder reactions, and the fact sheet does not describe the proposed rule in detail, so the exact changes from the proposal cannot be confirmed from those two documents alone.
Editor’s take
The final Medicare drug price negotiation rule is a housekeeping step with long-term weight. It replaces guidance with regulation, adds a rule for look-alike formulations, and sets the price floor for small biotech drugs. What it does not do is lower anyone’s drug costs this year, and CMS does not claim that it does. The two dates to watch are Dec. 5, when the rule takes effect, and Feb. 1, 2027, when CMS names up to 20 drugs for the next round. Until the selections are public, any claim about what the rule saves a particular enrollee rests on assumptions and not on the CMS documents.
This is general information, not medical or financial advice. The CMS rule text, fact sheet, and each plan’s formulary have the final word on coverage and prices.
